A Novo Nordisk designed trial reports that their 25 mg oral semaglutide taken once daily produced greater mean weight reduction than placebo over 64 weeks in adults with overweight or obesity.
For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist known as ecnoglutide yields a superior and sustained reduction in body weight versus placebo
While weight loss is commonly advised to enhance cardiovascular and joint health in older adults with obesity, it may also lead to bone loss, raising the risk of fractures that can diminish both quality and longevity of life.
A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body weight over a year, researchers reported Monday in The New England Journal of Medicine.
Popular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted
